Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. AFT Pharmaceuticals's Revenue for the
six
months ended in Mar. 2026 was A$114.7 Mil. AFT Pharmaceuticals's average Accounts Receivable for the
six
months ended in Mar. 2026 was A$47.1 Mil.
Hence, AFT Pharmaceuticals's Receivables Turnover for the
six
months ended in Mar. 2026 was 2.43.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
AFT Pharmaceuticals Receivables Turnover Related Terms
AFT Pharmaceuticals Receivables Turnover Historical Data
* Premium members only.
The historical data trend for AFT Pharmaceuticals's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:AFP vs ZTS, UTHR, VTRS: Receivables Turnover Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, AFT Pharmaceuticals's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AFT Pharmaceuticals Receivables Turnover vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, AFT Pharmaceuticals's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where AFT Pharmaceuticals's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AFT Pharmaceuticals (ASX:AFP) has a Receivables Turnover of 2.43 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on AFT Pharmaceuticals and its competitors. According to the industry distribution chart, AFT Pharmaceuticals ranks #537 out of 950 companies in the Drug Manufacturers industry, placing it in the top 56.5%.
Is AFT Pharmaceuticals' Receivables Turnover too high?
AFT Pharmaceuticals' current Receivables Turnover is 2.43. The Drug Manufacturers industry median Receivables Turnover is 5.07. AFT Pharmaceuticals' value of 2.43 is 52.1% below this industry median. Based on the distribution chart, AFT Pharmaceuticals ranks #537 out of 950 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, AFT Pharmaceuticals has a GF Score™ of 90/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does AFT Pharmaceuticals' Receivables Turnover compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, AFT Pharmaceuticals ranks #537 out of 950 companies for Receivables Turnover. This places AFT Pharmaceuticals in the lower half of its industry. The industry median Receivables Turnover is 5.07. AFT Pharmaceuticals' value of 2.43 is 52.1% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Drug Manufacturers company?
The median Receivables Turnover among Drug Manufacturers companies is 5.07, based on 950 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. AFT Pharmaceuticals's current Receivables Turnover of 2.43 is 52.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on AFT Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Receivables Turnover is 5.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. AFT Pharmaceuticals's current Receivables Turnover is 2.43. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AFT Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, AFT Pharmaceuticals (ASX:AFP) is currently considered Fairly Valued. The stock's GF Value™ is A$3.39, compared to a current price of A$3.19 — trading 5.9% below its estimated fair value. The current Receivables Turnover is 2.43 and 52.1% below the Drug Manufacturers industry median of 5.07. AFT Pharmaceuticals' overall GF Score™ is 90/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For AFT Pharmaceuticals (ASX:AFP), the current Receivables Turnover is 2.43 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is AFT Pharmaceuticals (ASX:AFP) Overvalued in 2026?
Based on GuruFocus' analysis, AFT Pharmaceuticals stock appears to be undervalued.
The current stock price of A$3.19 is trading 5.9% below its estimated GF Value™ of A$3.39.
GuruFocus considers AFT Pharmaceuticals to be Fairly Valued.
Key valuation signals for ASX:AFP:
Receivables Turnover: 2.43
GF Value™: A$3.39 vs. price of A$3.19 (5.9% below fair value)
Industry Position: 52.1% below the Drug Manufacturers median (#537 of 950)
No single metric tells the full story. See the ASX:AFP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
AFT Pharmaceuticals Ltd is a pharmaceutical distributor and developer of pharmaceutical intellectual property. Some of the products of the organization are Maxigesic dose forms, Capsaicin creams, Crystaderm, Kiwisoothe, Micolette, and others. The group has four operating segments based on geographical location being Australia, New Zealand, Asia, and the Rest of the world. It generates the majority of the revenue from Australia, which includes the sales and distribution activity relating to the Australian market.
90GF Score
Get the complete analysis for ASX:AFP
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:AFP has been successfully added to your 
